Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2495655 in Older Patients With Muscle Weakness and Recent Falls
NCT01604408Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2012
- Primary completion
- Sep 2013
- Countries
- 6
01
Overview
A Phase 2 trial of landogrozumab in muscle weakness, Sarcopenia, sponsored by Eli Lilly and Company. Started May 2012; status: completed.
02
Drugs
landogrozumab
03
Conditions
muscle weaknessSarcopenia
Beyond the preview
Go deeper on NCT01604408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01604408.